Baker Bros. Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Baker Bros. Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$136M	Hold	2,826,246	–	–	0.78%	17
2025 Q4	$117M	Buy	2,826,246 +1,577	+0.1%	+$63.3K	0.68%	23
2025 Q3	$110M	Hold	2,824,669	–	–	0.79%	15
2025 Q2	$78.2M	Buy	2,824,669 +6,346	+0.2%	+$162K	0.76%	17
2025 Q1	$62.6M	Hold	2,818,323	–	–	0.69%	17
2024 Q4	$55.7M	Hold	2,818,323	–	–	0.6%	22
2024 Q3	$70.4M	Hold	2,818,323	–	–	0.73%	21
2024 Q2	$52.6M	Buy	2,818,323 +8,746	+0.3%	+$164K	0.67%	23
2024 Q1	$55.4M	Hold	2,809,577	–	–	0.7%	23
2023 Q4	$49.3M	Hold	2,809,577	–	–	0.56%	23
2023 Q3	$48.8M	Hold	2,809,577	–	–	0.28%	22
2023 Q2	$39.6M	Buy	2,809,577 +10,000	+0.4%	+$134K	0.23%	28
2023 Q1	$30.1M	Hold	2,799,577	–	–	0.16%	30
2022 Q4	$41.9M	Hold	2,799,577	–	–	0.25%	27
2022 Q3	$35.9M	Hold	2,799,577	–	–	0.24%	32
2022 Q2	$27.1M	Hold	2,799,577	–	–	0.15%	39
2022 Q1	$27.8M	Hold	2,799,577	–	–	0.16%	44
2021 Q4	$33M	Hold	2,799,577	–	–	0.16%	45
2021 Q3	$31.9M	Hold	2,799,577	–	–	0.14%	50
2021 Q2	$39M	Hold	2,799,577	–	–	0.17%	44
2021 Q1	$51.8M	Hold	2,799,577	–	–	0.22%	39
2020 Q4	$49.5M	Hold	2,799,577	–	–	0.19%	35
2020 Q3	$42.9M	Hold	2,799,577	–	–	0.17%	37
2020 Q2	$71.3M	Hold	2,799,577	–	–	0.31%	26
2020 Q1	$43.3M	Hold	2,799,577	–	–	0.27%	28
2019 Q4	$31M	Hold	2,799,577	–	–	0.16%	40
2019 Q3	$23.8M	Hold	2,799,577	–	–	0.16%	38
2019 Q2	$37.9M	Sell	2,799,577 -200,423	-7%	-$3.11M	0.26%	36
2019 Q1	$54.2M	Hold	3,000,000	–	–	0.35%	30
2018 Q4	$84.3M	Hold	3,000,000	–	–	0.69%	15
2018 Q3	$76.5M	Hold	3,000,000	–	–	0.5%	22
2018 Q2	$52M	Buy	+3,000,000	New	+$54.3M	0.39%	24

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Baker Bros. Advisors's KNSA Position: Q1 2026 in Review

Baker Bros. Advisors held its Kiniksa Pharmaceuticals (KNSA) position steady in Q1 2026 at 2,826,246 shares worth $136M. The position accounts for 0.78% of the portfolio, ranked #17.

Baker Bros. Advisors first reported a position in KNSA in Q2 2018 and has held it in 32 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

Baker Bros. Advisors held 2,826,246 shares of Kiniksa Pharmaceuticals worth $136M as of Q1 2026.
Baker Bros. Advisors left its Kiniksa Pharmaceuticals share count unchanged in Q1 2026.
Kiniksa Pharmaceuticals made up 0.78% of Baker Bros. Advisors's portfolio in Q1 2026, its #17 holding.
Baker Bros. Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 32 quarters since.
228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Baker Bros. Advisors's 13F filing for Q1 2026, filed 15 May 2026.